Tirzepatide Burping & Sulfur Burps: FDA Label Rates + Mechanism Evidence

Burping on tirzepatide — the active ingredient in Mounjaro and Zepbound — is one of the most common side effects patients ask about online and one of the most clearly documented in the FDA labels. The Zepbound prescribing information^[1] lists eructation (the medical term for burping or belching) in §6.1 at 4–5% across the 5, 10, and 15 mg doses compared with 1% on placebo. The Mounjaro label^[2] reports a parallel signal: 2.5–3.3% on the same dose tiers vs 0.4% on placebo. The underlying mechanism is well characterized. Urva 2020^[3] measured a transient but profound gastric-emptying delay following tirzepatide dose escalation, comparable to selective long-acting GLP-1 receptor agonists. The Marathe 2013 Peptides review^[4] documents this as one of the cardinal pharmacologic effects of GLP-1 receptor activation. The downstream consequence for burping is straightforward: food sits longer in the stomach and proximal small bowel, the intra-gastric pressure builds against a tonically tight pylorus, and air swallowed during eating or generated by bacterial fermentation has nowhere to go but back up the esophagus. The minority of patients who describe a distinct sulfur or rotten-egg odor are reporting hydrogen sulfide (H2S), produced when the same delay gives sulfate-reducing bacteria — primarily Desulfovibrio species documented in Singh 2023^[10] — more time and more substrate to ferment sulfur-rich foods. This is not a sign of harm or that the medication is failing. It is a predictable second-order consequence of the same pharmacology that produces the appetite suppression and weight loss tirzepatide is prescribed for. The interventions are well-characterized and most patients see substantial improvement after titration completes.

At a glance

• Zepbound (FDA §6.1) — eructation in 1% placebo / 4% on 5 mg / 5% on 10 mg / 5% on 15 mg in the SURMOUNT-1/-3/-4 pooled obesity population^[1].
• Mounjaro (FDA §6.1) — eructation in 0.4% placebo / 3.0% on 5 mg / 2.5% on 10 mg / 3.3% on 15 mg in the SURPASS-pooled T2D population^[2]. Lower than Zepbound at matching doses partly because the T2D trials were shorter (40 weeks vs 72 in SURMOUNT-1) and the populations differed.
• Mechanism — tirzepatide is a dual GIP + GLP-1 receptor agonist; GLP-1 activation slows gastric emptying substantially during titration^[3][4], increasing intra-gastric dwell-time and bacterial-fermentation substrate.
• Sulfur or rotten-egg smell — comes from hydrogen sulfide (H2S) produced by sulfate-reducing bacteria, most prominently Desulfovibrio, when they ferment cysteine, methionine, and inorganic sulfate (broccoli, cabbage, garlic, onions, eggs, red meat)^[10].
• Compared with semaglutide — SURPASS-2 head-to-head (PMID 34170647) reported similar overall GI tolerability between tirzepatide and semaglutide^[6], and the Wegovy label lists eructation at ~9% — modestly higher than Zepbound's 4–5%.
• Strongest-evidence relief for the sulfur version — bismuth subsalicylate (Pepto-Bismol). The Suarez 1998 Gastroenterology paper^[9] showed it “markedly decreases hydrogen sulfide release in the human colon” by precipitating insoluble bismuth sulfide.
• Red flag — burping with severe upper-abdominal pain radiating to the back is a possible pancreatitis presentation and warrants same-day medical evaluation; this is a boxed-warning-adjacent risk in both Zepbound and Mounjaro labels.

What burping on tirzepatide looks like in trials

Both tirzepatide FDA labels report eructation as a documented adverse reaction in §6.1 (Adverse Reactions) at rates several times higher than placebo. The exact numbers come from the registration-trial safety tables.

Zepbound (obesity indication). The prescribing information^[1] reports the following rates for “Eructation (belching)” in the SURMOUNT-1/-3/-4 pooled obesity population:

• Placebo — 1%
• Tirzepatide 5 mg — 4%
• Tirzepatide 10 mg — 5%
• Tirzepatide 15 mg — 5%

Eructation is listed among “the most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND” in the highlights section of the label^[1].

Mounjaro (T2D indication). The prescribing information^[2] reports lower numerical rates in the SURPASS pooled T2D population, noting that “eructation (0.4%, 3.0%, 2.5%, 3.3%)” was reported more frequently in MOUNJARO-treated patients than placebo-treated patients across the 5, 10, and 15 mg doses. The lower numerical rate compared with Zepbound likely reflects three differences: SURPASS exposure topped out at 40 weeks vs 72 weeks for SURMOUNT-1, the T2D population differs from the obesity-only population, and many SURPASS arms had background metformin therapy.

Real-world FAERS signal. The Shen 2026 PLoS One pharmacovigilance analysis^[8] of FAERS spontaneous reports identified gastrointestinal adverse events as the dominant cluster for tirzepatide, with eructation and dyspepsia consistently appearing in disproportionality analyses. Real-world reporting tends to over-represent severe and persistent symptoms (mild transient burping rarely gets reported), so this signal adds confidence that the label rate is conservative for patient-experienced symptoms.

Mechanism: delayed gastric emptying creates the conditions for burping

The chain from injection to belch is short and well characterized: GLP-1 receptor activation slows gastric emptying → food and air sit longer in the stomach → intra-gastric pressure builds against tonically increased pyloric tone → gas (swallowed air plus fermentation gas) takes the path of least resistance upward through the lower esophageal sphincter → eructation.

The pharmacology. Tirzepatide is a once-weekly unimolecular agonist of both the GIP and GLP-1 receptors. GLP-1 receptors are densely expressed on enteric neurons in the gastric antrum, on the vagal afferents that coordinate gastric motility, and along the pylorus. Receptor activation reduces antral contractility and increases pyloric tone, which delays gastric chyme transfer into the duodenum. The Marathe 2013 Peptides review^[4] characterizes this as a “cardinal pharmacologic effect” of GLP-1 in health and disease, present in both endogenous GLP-1 and pharmacologic GLP-1 receptor agonists.

The tirzepatide-specific data. The Urva 2020 Diabetes Obesity and Metabolism paper^[3] was the canonical PK study of tirzepatide's gastric- emptying effect. The authors measured a transient but profound delay following dose escalation, with magnitude comparable to selective long-acting GLP-1 receptor agonists. Importantly, the effect is “transient”: it peaks during titration and attenuates substantially by steady-state dosing, which is why burping is typically worst in the first 4–8 weeks after each dose step and improves once the dose is held stable.

The added GIP agonism. Tirzepatide's GIP receptor activation does not appear to add meaningfully to the gastric-emptying delay beyond what GLP-1 receptor activation alone produces — the magnitude of the emptying delay in Urva 2020 was within the range reported for selective long-acting GLP-1 receptor agonists like semaglutide and dulaglutide. This is consistent with the SURPASS-2 head-to-head^[6] finding of broadly similar overall GI tolerability between tirzepatide and semaglutide at therapeutically equivalent doses.

Why the burping presents as belching specifically. When gastric emptying is slowed, swallowed air (aerophagia, roughly 1–2 mL of air per swallow) and gas generated by bacterial fermentation accumulate in the stomach faster than they can be passed downstream through the pylorus. The gastric bubble enlarges. Increased intra-gastric pressure eventually overcomes lower-esophageal-sphincter tone and gas escapes upward as a burp. This is mechanistically distinct from flatulence (which is gas that did make it through the pylorus into the small bowel and colon) and from the bloating sensation (which is intra-luminal distension without efficient gas escape in either direction).

Why some burps smell like sulfur or rotten eggs

The minority of tirzepatide patients who report a distinct sulfur or rotten-egg odor are describing hydrogen sulfide (H2S). The human nose detects H2S at parts-per-billion concentrations, well below any toxic threshold — it is the same gas that gives rotten eggs and sulfur springs their smell.

Where the H2S comes from. The healthy human gut microbiome contains sulfate-reducing bacteria (SRB) at low to moderate abundance. Desulfovibrio is the best-characterized genus; Singh 2023^[10] reviews the species' role as the dominant SRB in the human gut. These bacteria use inorganic sulfate or sulfur-containing amino acids as terminal electron acceptors in anaerobic respiration and release H2S as a metabolic byproduct.

The substrate. SRB consume two main substrate classes: sulfur-containing amino acids (cysteine, methionine, taurine) released during digestion of high-protein meals (eggs, red meat, poultry, dairy, whey protein, fish), and inorganic sulfate from cruciferous vegetables (broccoli, cabbage, Brussels sprouts, cauliflower, kale), allium vegetables (onions, garlic, leeks), and sulfite preservatives (dried fruits, wine, processed meats).

Why tirzepatide tips the balance. Under ordinary gastric emptying (90–120 minute half-time), most sulfur substrate is absorbed in the small intestine before reaching SRB-rich distal compartments. Under GLP-1-slowed emptying during tirzepatide titration (potentially 3–5+ hour half-time per Urva 2020^[3]), substantially more sulfur substrate persists long enough for SRB metabolism. The result is more H2S, some of which migrates back proximally and is expelled with the burp.

How honest is the evidence here? Patient-reported sulfur burps on GLP-1 drugs are widely documented in social-media discussion and clinical practice but no randomized trial has specifically measured H2S breath-test concentrations or stool sulfide output on tirzepatide. The mechanism explanation rests on (a) the documented gastric-emptying delay^[3], (b) the well-characterized H2S biochemistry of Desulfovibrioand other SRB^[10], and (c) the food-trigger reproducibility patients consistently describe. Treat the rotten-egg smell explanation as mechanistically plausible and consistent with the broader sulfur-burp literature rather than as a tirzepatide-specific RCT finding.

What the Zepbound and Mounjaro FDA labels say

Both tirzepatide prescribing information documents address eructation directly. The exact label language matters because it sets the boundary between expected adverse effect and clinically actionable problem.

Zepbound highlights section. “The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease”^[1]. Eructation made the ≥5% cutoff list at the 10 and 15 mg doses.

Mounjaro §6.1 verbatim. “The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%)”^[2].

What neither label says. Neither prescribing information uses the words “sulfur” or “rotten egg” in the eructation entry. The label captures eructation as an event; the H2S explanation for the subset of patients who notice an odor is downstream microbiology, not a regulator-adjudicated adverse-event category. Both labels do list dyspepsia and gastroesophageal reflux disease at meaningful rates above placebo, which often co-present with eructation in the same patients.

How tirzepatide burping compares to semaglutide and retatrutide

Tirzepatide vs semaglutide. SURPASS-2^[6] was the open-label 40-week head-to-head trial of tirzepatide (5, 10, 15 mg) vs semaglutide 1 mg in 1,879 adults with type 2 diabetes on background metformin. The overall GI tolerability profiles were strikingly similar: nausea 17–22% on tirzepatide vs 18% on semaglutide; vomiting 6–10% vs 8%. The Wegovy semaglutide 2.4 mg label lists eructation at roughly 9%, modestly higher than Zepbound's 4–5%. Read together, the data suggest semaglutide produces slightly more eructation than tirzepatide at obesity-indication doses, but the absolute gap is small. If you switch from Ozempic or Wegovy for burping, expect some improvement but not a complete resolution; the underlying mechanism is the same drug class.

Tirzepatide vs retatrutide. Retatrutide is an investigational triple agonist (GLP-1 + GIP + glucagon) in late-phase trials. The Urva 2023 Diabetes Obesity and Metabolism pharmacokinetic study^[7] documented that retatrutide also produces a gastric-emptying delay comparable to other long-acting GLP-1 receptor agonists. In the Jastreboff 2023 phase 2 obesity trial, gastrointestinal AEs (nausea, diarrhea, vomiting, constipation) were the dominant cluster, consistent with the class. Eructation rates have not been broken out separately in the phase 2 publication. The mechanism is the same, so a similar burping profile is expected when retatrutide reaches the FDA-labeled-doses stage.

For the broader head-to-head, see our retatrutide vs tirzepatide evidence review.

Diet adjustments that reduce burping

Dietary intervention is the single highest-yield response to tirzepatide burping. The targets fall into two buckets: reduce the air and gas going in, and reduce the sulfur substrate going to SRB.

• Smaller, more frequent meals. 5–6 smaller meals reduce peak intra-gastric volume and intra-gastric pressure; tirzepatide's appetite suppression makes this easier than it sounds. This is the most consistent recommendation from GLP-1 patient education materials.
• Slow down. Each swallow brings down roughly 1–2 mL of air. Rapid eating, talking while eating, drinking with a straw, chewing gum, and carbonated beverages all increase aerophagia and add directly to the gas burden.
• De-emphasize high-sulfur foods during the worst weeks. If sulfur burps are specifically the problem, temporarily reducing eggs, red meat, whey protein, cruciferous vegetables (broccoli, cabbage, cauliflower, Brussels sprouts), allium vegetables (onions, garlic, leeks), and sulfite-preserved foods (dried fruits, wine, processed meats) can blunt the H2S production. This is targeted symptom management for the worst titration weeks, not a long-term dietary prescription — these foods have meaningful nutritional value and many are actively recommended on a GLP-1 high-protein diet.
• Don't lie down after eating. Staying upright for 2–3 hours after meals (which also helps with reflux on tirzepatide) reduces the proximal gas accumulation that drives burping.
• Stay hydrated. 2.5–3 L of non-caffeinated fluid per day supports normal motility and helps fiber move stool through, which downstream reduces fermentation-gas pressure.
• Pace fiber, don't crash it. Aggressively increasing fiber overnight (psyllium, raw cruciferous salads, beans) on top of tirzepatide-slowed motility predictably produces more burping and bloating. Ramp fiber over 2–3 weeks.

OTC relief options when diet isn't enough

For the sulfur-smelling subset specifically, the strongest-evidence OTC intervention is bismuth subsalicylate (Pepto-Bismol). The Suarez 1998 Gastroenterology paper^[9] measured a marked decrease in hydrogen sulfide release in the human colon following bismuth subsalicylate administration; the mechanism is that bismuth ions precipitate insoluble bismuth sulfide, removing H2S from the gas phase. Short-term use (a few days during the worst titration week) is well-tolerated; chronic daily use is not recommended due to salicylate accumulation and the harmless but alarming black-tongue/black-stool cosmetic effect.

Simethicone (Gas-X, Mylicon) is widely used for general burping and bloating. Mechanism is anti-foaming (it reduces the surface tension of small gas bubbles, allowing them to coalesce and pass), not anti-H2S. It is reasonable for the odorless-burping presentation but does not specifically address the sulfur smell.

Activated charcoal binds gases including H2S and is sometimes recommended; the human evidence is limited but the safety profile is benign at standard OTC doses. Take it away from tirzepatide and other medications because it can bind drugs as well as gases.

Probiotics have modest evidence in functional GI symptoms broadly. Strains studied for bloating and gas (Lactobacillus rhamnosus, Bifidobacterium lactis) have not been specifically trialed for GLP-1 eructation; reasonable to try for 4–6 weeks but not the first lever.

When burping is a red flag

Most tirzepatide burping is benign and titration-related. Three presentations change that calculus and warrant same-day medical evaluation.

• Burping with severe upper-abdominal pain radiating to the back. This is a classic pancreatitis presentation. Both Zepbound and Mounjaro labels include acute pancreatitis as a §5.2 warning; discontinue tirzepatide and seek same-day evaluation. Lipase elevation is the diagnostic standard.
• Burping with right-upper-quadrant pain after fatty meals. Could indicate gallstone disease (cholelithiasis) or acute cholecystitis. Both tirzepatide labels acknowledge gallbladder disease as a §5.5 (Zepbound) and §5.6 (Mounjaro) warning, with elevated cholelithiasis and cholecystitis rates in the SURMOUNT and SURPASS trials. RUQ ultrasound is the standard workup.
• Burping with persistent vomiting and inability to keep down fluids for 24+ hours. Raises concern for ileus, severe gastroparesis, or gastric outlet obstruction. The Mounjaro and Zepbound labels both list ileus as a postmarketing adverse reaction. Hydration failure on tirzepatide also raises the §5.3 acute kidney injury risk — same-day evaluation indicated.

Persistent uncomplicated burping that does not respond to diet plus OTC measures past month 3 of stable dosing warrants a prescriber conversation but is not a same-day emergency. Options include extending each titration step from 4 to 8 weeks, holding at a lower maintenance dose, evaluating for small intestinal bacterial overgrowth (SIBO), or switching to a different GLP-1.

Timeline: when does the burping improve?

The same Urva 2020 PK data^[3] that establishes the gastric-emptying delay also explains the timeline. The emptying delay is described as “transient” and attenuates with continued dosing at a stable dose. In practice:

• Weeks 1–4 (2.5 mg start dose): burping typically mild; many patients notice eructation but it is not yet a dominant symptom.
• Weeks 5–8 (5 mg first maintenance step): burping commonly peaks here and in the days following each subsequent dose escalation. Sulfur-smelling burps if they appear at all typically emerge in this window.
• Weeks 9–16 (titration to 10 or 15 mg): each dose step recapitulates a smaller spike in burping frequency that attenuates over 2–3 weeks at the new stable dose.
• Month 4 and beyond: for most patients, burping settles to a low background frequency. Patients who report persistent burping at this stage often have identifiable dietary triggers (a switch to a much higher protein intake, addition of a daily whey protein shake, regular cruciferous-heavy meals) or baseline GI conditions (GERD, IBS, SIBO).

For a fuller cross-side-effect timeline see the GLP-1 side effect timeline tool.

Practical takeaway

Tirzepatide burping is real, labeled, and mechanistically well-explained. The Zepbound label puts the rate at 4–5% across the 5, 10, and 15 mg obesity doses^[1]; Mounjaro at 2.5–3.3% across the same T2D doses^[2]. The mechanism is the gastric-emptying delay that Urva 2020^[3] documented and the GLP-1 receptor biology that Marathe 2013^[4] reviewed. The sulfur or rotten-egg subset reflects hydrogen sulfide produced by sulfate-reducing gut bacteria^[10] fed by high-protein meals and cruciferous vegetables during slowed transit. First-line management is dietary: smaller meals, slower eating, less carbonation, temporarily reduce sulfur-rich foods during the worst titration weeks, ramp fiber slowly. OTC second line is bismuth subsalicylate for sulfur burps specifically (Suarez 1998 mechanism^[9]) and simethicone for the odorless presentation. Red flags — burping with severe upper-abdominal pain radiating to the back, RUQ pain after fatty meals, or persistent vomiting — warrant same-day evaluation. Most patients see substantial improvement after titration completes.

Related WLR articles

• Ozempic sulfur burps and burping: causes, foods, OTC relief evidence review — sister article on the semaglutide side of the class.
• Ozempic acid reflux and GERD: FDA label rates, mechanism, and practical relief — the related upper-GI presentation that often co-occurs with burping.
• Mounjaro vs Zepbound: tirzepatide disambiguation — same molecule, different brands, different §6.1 tables.
• Mounjaro constipation: SURPASS-1 rates, mechanism, and evidence-based relief — the other-end-of-the-GI-tract side effect on the same drug.
• Mounjaro nausea management evidence review — the dominant tirzepatide GI side effect, often co-presents with burping.
• Retatrutide vs tirzepatide head-to-head evidence — cross-class comparison including the GI safety profile.
• GLP-1 side effect questions answered (hub) — cross-cutting Q&A index across all GLP-1 side effects.
• GLP-1 side effect timeline tool — when each side effect peaks and resolves, by drug and week.

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about managing tirzepatide side effects should always be made with your prescribing clinician, particularly if you have a history of pancreatitis, gallbladder disease, gastroparesis, severe GERD, IBS, or are taking multiple other medications. Seek same-day medical evaluation for burping accompanied by severe upper-abdominal pain radiating to the back, right-upper-quadrant pain after fatty meals, or persistent vomiting with inability to keep down fluids for 24+ hours.